Xeloda
What Xeloda is used for
Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment of metastatic colorectal cancer. Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Xeloda
- Active substance
- capecitabine
- Disease area
- Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01BC06
- Marketing authorisation holder
- CHEPLAPHARM Arzneimittel GmbH
- Authorised in the EU since
- 2001
Official information
In India
- Capecitabine: 60 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xeloda used for?
Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment of metastatic colorectal cancer. Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of pa…
What is the active substance in Xeloda?
Xeloda contains capecitabine.
Who makes Xeloda?
The EU marketing authorisation holder is CHEPLAPHARM Arzneimittel GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU